Zanubrutinib shows durable efficacy in CLL/SLL with 17p deletions, according to 5-year SEQUOIA trial data.

Pharmaceutical Co. Ltd.’s LYN/BTK dual inhibitor, DZD-8586, saw tumor shrinkage in 94.1% of patients with relapsed or ...

Switching patients with chronic lymphocytic leukemia (CLL) from ibrutinib to zanubrutinib has led to fewer cardiac side effects and a reduced workload for Mohit Narang, MD, managing partner at ...

Panelists discuss the primary access challenges in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) treatment, including financial barriers and health care system limitations, and how ...

Chronic lymphocytic leukemia (CLL) is due to the unremitting accumulation of neoplastic CD5 + B cells in blood, bone marrow, and lymphoid tissues. The prognosis of patients with this form of leukemia ...

If you or a loved one were exposed to benzene at work and were diagnosed with cancers such as leukemia, myelodysplasia (MDS), ...

Zanubrutinib plus venetoclax elicited durable responses in patients with treatment-naïve CLL or SLL and high-risk genetic features.

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...

Five early-career Fred Hutch/UW researchers received prestigious Young Investigator Awards from Conquer Cancer, the ASCO Foundation during this year's annual meeting of the American Society of ...

Defects in the DNA damage sensors, particularly in the ataxia telengiectasia mutated (ATM)/TP53 pathways, confer resistance to standard chemotherapic agents used in CLL [4] that inflict DNA damage ...

The safety profile was consistent with previous studies, with no new safety signals. These results reinforce BeOne Medicines ...

Apr. 23, 2025 — Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer ...